Evidence map›Paper›PMID 33784981›Full record

ArticleBMC medical research methodology2021

Comparing the use of aggregate data and various methods of integrating individual patient data to network meta-analysis and its application to first-line ART.

Steve Kanters, Mohammad Ehsanul Karim, Kristian Thorlund, Aslam H Anis, Michael Zoratti, Nick Bansback

Abstract read
In one paragraph

Article in BMC medical research methodology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Article
  2. Article
  3. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Steve KantersSchool of Population and Public Health, University of British Columbia, 2206 E Mall, Vancouver, British Columbia, Canada. skanters@raincity-analytics.com.ORCID 0000-0003-0322-5398
Mohammad Ehsanul KarimSchool of Population and Public Health, University of British Columbia, 2206 E Mall, Vancouver, British Columbia, Canada.
Kristian ThorlundDepartments of Health Research Methods, Evidence and Impact, McMaster University, Hamilton, Canada.
Aslam H AnisSchool of Population and Public Health, University of British Columbia, 2206 E Mall, Vancouver, British Columbia, Canada.
Michael ZorattiDepartments of Health Research Methods, Evidence and Impact, McMaster University, Hamilton, Canada.
Nick BansbackSchool of Population and Public Health, University of British Columbia, 2206 E Mall, Vancouver, British Columbia, Canada.

Funding

CIHR
6 · The paper itself

Abstract

backgroundThe 2018 World Health Organization HIV guidelines were based on the results of a network meta-analysis (NMA) of published trials. This study employed individual patient-level data (IPD) and aggregate data (AgD) and meta-regression methods to assess the evidence supporting the WHO recommendations and whether they needed any refinements.

methodsAccess to IPD from three trials was granted through ClinicalStudyDataRequest.com (CSDR). Seven modelling approaches were applied and compared: 1) Unadjusted AgD network meta-analysis (NMA) - the original analysis; 2) AgD-NMA with meta-regression; 3) Two-stage IPD-AgD NMA; 4) Unadjusted one-stage IPD-AgD NMA; 5) One-stage IPD-AgD NMA with meta-regression (one-stage approach); 6) Two-stage IPD-AgD NMA with empirical-priors (empirical-priors approach); 7) Hierarchical meta-regression IPD-AgD NMA (HMR approach). The first two were the models used previously. Models were compared with respect to effect estimates, changes in the effect estimates, coefficient estimates, DIC and model fit, rankings and between-study heterogeneity.

resultsIPD were available for 2160 patients, representing 6.5% of the evidence base and 3 of 24 edges. The aspect of the model affected by the choice of modeling appeared to differ across outcomes. HMR consistently generated larger intervals, often with credible intervals (CrI) containing the null value. Discontinuations due to adverse events and viral suppression at 96 weeks were the only two outcomes for which the unadjusted AgD NMA would not be selected. For the first, the selected model shifted the principal comparison of interest from an odds ratio of 0.28 (95% CrI: 10.17, 0.44) to 0.37 (95% CrI: 0.23, 0.58). Throughout all outcomes, the regression estimates differed substantially between AgD and IPD methods, with the latter being more often larger in magnitude and statistically significant.

conclusionsOverall, the use of IPD often impacted the coefficient estimates, but not sufficiently as to necessitate altering the final recommendations of the 2018 WHO Guidelines. Future work should examine the features of a network where adjustments will have an impact, such as how much IPD is required in a given size of network.

Indexed as

Research DesignResearch ReportAnti-Retroviral AgentsHIV InfectionsHumansNetwork Meta-Analysis as TopicOdds RatioRegression AnalysisAnti-Retroviral AgentsEcological fallacyGuideline developmentHIVIndividual patient dataIPDNetwork meta-analysesOne-stage NMATwo-stage NMA

Identifiers

PMID33784981
PMCPMC8008675

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.